Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2268

Anti-IL6-Receptor Tocilizumab in Graves’ Orbitopathy. Multicenter Study of 46 Patients

9:00AM-11:00AM: Abstract Number: 2275

Autoimmune Encephalitis with Concomitant Systemic Rheumatologic Auto-Antibodies

9:00AM-11:00AM: Abstract Number: 2259

BONE Sarcoidosis: A French Case Control Study

9:00AM-11:00AM: Abstract Number: 2277

Colchicine: An Effective Treatment Option for Unclassified Autoinflammatory Diseases in Children

9:00AM-11:00AM: Abstract Number: 2278

Cryopyrinopathy across Generations: Longterm Disease Outcome

9:00AM-11:00AM: Abstract Number: 2258

Defining Characteristics of Patients with Overlap between Sarcoidosis and Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 2263

Differentiated Phenotypes at Diagnosis of Sarcoidosis According to the Scadding Classification: Analysis in 1230 Patients

9:00AM-11:00AM: Abstract Number: 2273

High Dose Intravenous Methylorednisolone Induces Rapid Improvement in Severe Non-Infectious Uveitis. a Multicenter Study of 120 Patients

9:00AM-11:00AM: Abstract Number: 2262

Increased Risk of Sarcoidosis Among Patients with Celiac Disease: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2269

Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients

9:00AM-11:00AM: Abstract Number: 2271

Long-Term Efficacy and Safety of Adalimumab By Immunosuppressant Use in Patients with Non-Infectious Uveitis

9:00AM-11:00AM: Abstract Number: 2261

Long-Term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013

9:00AM-11:00AM: Abstract Number: 2265

Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-Related Uveitis

9:00AM-11:00AM: Abstract Number: 2282

Measurement of the Pro-Coagulant Activity of Microparticles in Patients with Inflammatory Rheumatic Diseases: Prospective Study

9:00AM-11:00AM: Abstract Number: 2264

Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases

9:00AM-11:00AM: Abstract Number: 2272

Missed Opportunity? Evaluation for Systemic Autoimmune Diseases in Patients with Uveitis May Not be Optimal: 5-Year Analysis of Patients Being Seen in a Tertiary Medical Center

9:00AM-11:00AM: Abstract Number: 2260

Musculoskeletal Sarcoidosis: A 15-Year Experience from a Tertiary Care Center in the US

9:00AM-11:00AM: Abstract Number: 2267

Ocular and Systemic Features in 262 Patients with Systemic Sarcoidosis and Its Correlation with Iwos Criteria

9:00AM-11:00AM: Abstract Number: 2257

Prevalence and Distinct Clinical Phenotype of Concomitant Sarcoidosis in Other Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2274

Refractory and Severe Uveitic Cystoid Macular Edema Improves with Tocilizumab in Different Immune Mediated Diseases

9:00AM-11:00AM: Abstract Number: 2256

Rheumatic Diseases Associated with Neuromyelitis Optica Spectrum Disorders (NMOSD): Prevalence, Clinical, Laboratory and Imaging Characteristics

9:00AM-11:00AM: Abstract Number: 2276

Risk of Hemorrhagic Strokes in Patients with Adenosine Deaminase 2 Deficiency

9:00AM-11:00AM: Abstract Number: 2266

Serum 1,25(OH)2 Vitamin D and 25(OH) Vitamin D Ratio for the Diagnosis of Sarcoidosis-Related Uveitis

9:00AM-11:00AM: Abstract Number: 2279

Therapeutic Value of Canakinumab in Patients with Yao Syndrome

9:00AM-11:00AM: Abstract Number: 2280

Transcriptomic Analysis of Hidradenitis Suppurativa Skin Demonstrates Dysregulation of Antimicrobial Proteins and Inflammatory Pathways

9:00AM-11:00AM: Abstract Number: 2281

Treatment Choices and Response Rates of SAPHO Syndrome: Single Center Case Series

9:00AM-11:00AM: Abstract Number: 2270

Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].